Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation

@inproceedings{Narayanan2013DiscoveryAP,
  title={Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation},
  author={Ramesh Narayanan and Muralimohan Yepuru and Christopher C. Coss and Zhongzhi Wu and Matthew N. Bauler and Christina M. Barrett and Michael L. Mohler and Yun Wang and Juhyun Kim and L. Michael Snyder and Yali He and Nelson Levy and Duane D. Miller and James T Dalton},
  booktitle={PloS one},
  year={2013}
}
Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation. Increased expression, activating mutations and rearrangement fusions of RTKs lead to cancer, inflammation, pain, neurodegenerative diseases, and other disorders. Activation or over-expression of ALK, ROS1, TRK (A, B, and C), and RET are associated with oncogenic phenotypes of their respective tissues… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
12 Citations
51 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…